Recommended therapies for restenosis

Bibliography

• MEDICAL DATA INTERNATIONAL: Coronary stents: near the top of the market? Med. Pro Month (1997) 6–7:173–177.
   Google Scholar
• GURA T: Infections: a cause of artery-clogging plaques. Science (1998) 281:35–37.
   PubMedGoogle Scholar
• LIBBY P: Role of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation (1997) 96:4095–4103 .
   PubMed Web of Science ®Google Scholar
• EPSTEIN SE, SPEIR E, UNGER EF et al.: The basis of mo-lecular strategies for treating coronary restenosis after angioplasty. J. Am. Coll. Cardiol. (1994) 23:1278–1288.
   PubMed Web of Science ®Google Scholar
• ••A review detailing some strategies for the treatment ofrestenosis.
   Google Scholar
• LINDNER V, LAPPI DI, BAIRD A et al.: Role of basic fibro-blast growth factor in vascular lesion formation. Circ. Res. (1991) 68:106–113.
   PubMed Web of Science ®Google Scholar
• FERNS GAA, STEWERT-LEE AL, ANGGARD EE: Arterial re-sponse to mechanical injury: balloon catheter de-endothelialization. Atherosclerosis (1992) 92:89–104.
   PubMedGoogle Scholar
• ALBERTS GF, DEBBIE KW, HSU KA et al.: Differential regulation of acidic and basic fibroblast growth factor gene expression in fibroblast growth factor treated rat aortic smooth muscle cells. Circ. Res. (1994) 75:261–267.
   PubMedGoogle Scholar
• MII S, WARE JA, KENT KC: Transforming growth factor beta inhibits human vascular smooth muscle cell growth and migration. Surgery (1993) 114:464–470.
   PubMed Web of Science ®Google Scholar
• WANG J, NIU W, WITTE DP et al.: Overexpression of insulin-like growth factor binding protein-4 (IGFBP-4) in smooth muscle cells of transgenic mice through a smooth muscle alpha-actin-IGFBP-4 fusion gene in-duces smooth muscle hypoplasia. Endocrinology (1998) 139:2605–2614.
   PubMed Web of Science ®Google Scholar
• YE L, MORA R, AKHAYANI N et al.: Growth factor and cy-tokine regulated hyaluronan-binding protein TSG-6 is localized to the injury induced rat neointima and con-fers enhanced growth in vascular smooth muscle cells. Circ. Res. (1997) 81:289–296.
   PubMedGoogle Scholar
• SARZANI R, BRECHER P, CHOBANIAN AV: Growth factor expression in aorta of normotensive and hypertensive rats. J. Clin. Invest. (1989) 83:1404–1408.
   PubMed Web of Science ®Google Scholar
• MOSES MA, KLAGSBRUN M, SHING Y: The role of growth factors in vascular cell development and differentia-tion. Int. Rev. Cytol. (1995) 161:1–48.
   PubMedGoogle Scholar
• ••A review on the involvement of growth factors in vascularcell proliferation.
   Google Scholar
• OWENS GK, WISE G: Regulation of differentiation/maturation in vascular smooth muscle cells by hormones and growth factors. Agents Actions (1997) 48:3–24.
   PubMedGoogle Scholar
• ••A review detailing the role of hormones and growth factorsin vascular smooth muscle differentiation and maturation.
   Google Scholar
• HALLORAN BG, SO BJ, BAXTER BJ: Platelet derived growth factor is a cofactor in the induction of 1 alpha (0 procollagen expression by transforming growth factor beta in smooth muscle cells. J. Vasc. Surg. (1996) 23:767–773.
   PubMedGoogle Scholar
• PALMER H, LIBBY P: Interferon beta. A potential auto-crine regulator of human vascular smooth muscle cell growth. Lab. Invest. (1992) 66:715–721.
   Google Scholar
• FILONZI EL, ZOELLNER H, STANTON H et al.: Cytokine regulation of granulocyte macrophage colony stimu-lating factor and macrophage colony stimulating fac-tor production in human arterial smooth muscle cells. Atherosclerosis (1993) 99:241–252.
   PubMed Web of Science ®Google Scholar
• LYNCH CM, CLOWES MM, OSBORNE WRA et al.: Long term expression of human adenosine deaminase in vascular smooth muscle cells of rats, a model for gene therapy. Proc. Natl. Acad. Sci. USA (1992) 89:1138–1142.
   PubMed Web of Science ®Google Scholar
• GEARY RL, LYNCH CM, VERGEL S et al.: Human gene ex-pression in baboons using vascular grafts seeded in retrovirally transduced smooth muscle cells. Circula-tion (1993) 88sI:1–81.
   Google Scholar
• FOROUGH R, KOYAMA N, NASENSTAB D et al.: Overex-pression of tissue inhibitor of matrix metalloprote-inase I inhibits vascular smooth muscle functions in vitro and in vivo. Circ. Res. (1996) 79:812–820.
   PubMed Web of Science ®Google Scholar
• MIANO JM, VLASIC N, TOTA RR et al: Smooth muscle cellimmediate-early gene and growth factor activation fol-lows vascular injury. A putative in vivo mechanism for autocrine growth. Arterioscler. Thromb. (1993) 13:211–219.
   PubMed Web of Science ®Google Scholar
• BAUTERS C, DEGROOTE P, ADAMANTIDIS M et al.:Proto-oncogene expression in rabbit aorta after wall injury. First maker of the cellular process leading to restenosis after angioplasty? Eur. Heart J. (1992) 13:556–559.
   Google Scholar
• MARMUR JD, POON M, ROSSIKHINA M etal.: Induction ofPDGF-responsive genes in vascular smooth muscle: implications for the early response to vessel injury. Circulation (1992) 86\(Suppl. 11053–60.
   Google Scholar
• TAUBMAN M, ROLLINS B, POON M et al.: mRNA accumu-lates rapidly in aortic injury and in platelet derived growth factor stimulated vascular smooth muscle cells. Circ. Res. (1992) 70:314–325.
   PubMed Web of Science ®Google Scholar
• INDOLFI C, AVVEDIMENTO EV, RAPACCIUOLO A et al.: Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nature Med. (1995) 1:541–545.
   PubMed Web of Science ®Google Scholar
• CHANG MW, BARR E, SALTZER J et al.: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science (1995) 267:518–522.
   PubMed Web of Science ®Google Scholar
• CHANG MW, BARR E, LU MM et al.: Adenovirus mediatedoverexpression of the cyclin/cyclin-dependent kinase inhibitor p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat ca-rotid artery model of balloon angioplasty. J. Clin. Invest. (1995) 96:2260–2268.
   PubMed Web of Science ®Google Scholar
• YANG Z-Y, SIMARI RD, PERKINS ND et al.: Role of the p21 cyclin dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl. Acad. Sci. USA (1996) 93:7905–7910.
   PubMedGoogle Scholar
• ANTONIADES H, GALANOPOULOS T, NEVILLE- GOLDENJ et al: p53 expression during normal tissue regenera-tion in response to acute cutaneous injury in swine. J. Clin. Invest. (1994) 93:2206–2214.
   PubMedGoogle Scholar
• MULLER DWM: The role of proto-oncogenes in coro-nary restenosis. Prog. Cardiovas. Dis. (1997) 40:117–128.
   PubMedGoogle Scholar
• ••Details the possible role of proto-oncogenes in develop-ment of restenosis.
   Google Scholar
• WEIR L, CHEN D, PASTORE C et al.: Expression of gax, a growth arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the prolifera-tive response to balloon injury. J. Biol. Chem. (1995) 270:5457–5461.
   Google Scholar
• MAILLARD L, WALSH K: Growth arrest homeobox gene gax: a molecular strategy to prevent arterial resteno-sis. Schweig. Med. Wochenschr. (1996) 126:1721–1726.
   PubMedGoogle Scholar
• WALSH W, PERLMAN H: Molecular strategies to inhibit restenosis: modulation of the vascular myocyte phe-notype. Semin. Intervent. Cardiol. (1996) 1:173–179.
   PubMedGoogle Scholar
• ••Provides an insight to factors that regulate vascular myocytephenotype.
   Google Scholar
• ROUAULT JP, SAMARUT C, DURET L et al.: Sequence analysis reveals that the BTG1 anti-proliferative gene is conserved throughout evolution in its coding and 3' non-coding regions. Gene (1993) 129:303–306.
   PubMedGoogle Scholar
• BORRELLI E, HEYMAN R, HSI M et al.: Targeting of an in-ducible toxic phenotype in animal cells. Cell Biol. (1988) 85:7572–7576.
   Google Scholar
• VON DER LEYEN HE, GIBBONS GH, MORISHITA R et al.: Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. Sci. (1995) 92:1137–1141.
   Google Scholar
• NEWMAN KD, DUNN PF, OWEN JW et al.: Adenovirus mediated gene transfer into normal rabbit arteries re-sults in prolonged vascular cell activation, inflamma-tion, and neointimal hyperplasia. J. Clin. Invest. (1995) 96:2955–2965.
   PubMed Web of Science ®Google Scholar
• STEIN CA, COHEN JS: Oligodeoxynucleotides as inhibi-tors of gene expression: a review. Cancer Res. (1988) 48:2659–2668.
   PubMed Web of Science ®Google Scholar
• NECKERS L, WHITESELL L, ROSOLEN A et al.: Antisense inhibition of oncogene expression. Crit. Rev. Oncogen. (1992) 3:175–231.
   PubMedGoogle Scholar
• WEINTRAUB SJ, PRATER CA, DEAN DC et al.: Retinoblas-toma protein switches the E2F site from positive to negative elements. Nature (1992) 358:259–261.
   PubMed Web of Science ®Google Scholar
• PAGANO M, DRAETTA G, DURR J. Association of cdk-2 kinase with the transcription factor E2F during S phase. Science (1992) 255:1144–1147.
   Google Scholar
• KINDY MS, SONENSHEIN GE: Regulation of oncogene expression in cultured aortic smooth muscle cells: post-transcriptional control of c-myc mRNA. J. Biol. Chem. (1986) 261:12865–12868.
   PubMed Web of Science ®Google Scholar
• BENNETT MR, EVAN GI, NEWBY AC: Deregulation ex-pression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscles by se-rum reduction, interferon 7, heparin, and cyclic nu-cleotide analogues and induces apoptosis. Circ. Res. (1994) 74:525–536.
   PubMed Web of Science ®Google Scholar
• PARKES JL, CARDELL R, HUBBARD FC et al.: Cultured hu-man atherosclerotic plaque smooth muscle cells re-tain transforming potential and display enhanced expression of the myc proto-oncogene. Am. J. Pathol (1991) 138:765–775.
   PubMedGoogle Scholar
• SHI Y, FARD A, GALEO A et al.: Transcatheter delivery of c-myc antisense oligomers reduces neointimal forma-tion in a porcine model of coronary artery balloon in-jury. Circulation (1994) 90:944–951.
   PubMed Web of Science ®Google Scholar
• GUNN J, HOLT CM, FRANCIS SE et al.: The effect of oligo-nucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Circ. Res. (1997) 80:520–531.
   PubMed Web of Science ®Google Scholar
• SIMONS M, ROSENBERG RD: Antisense nonmuscle my-osin heavy chain and c-myboligonucleotides suppress smooth muscle proliferation in vitro. Circ. Res. (1992) 70: 835–843.
   PubMed Web of Science ®Google Scholar
• SHI Y, HUTCHINSON HG, HALL DJ et al.: Down regula-tion of c-myc expression by antisense oligonucleo-tides inhibits proliferation of human smooth muscle cells. Circulation (1993) 88:1190–1195.
   PubMed Web of Science ®Google Scholar
• BENNETT MR, ANGLIN S, MCEWAN JR et al.: Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo in c-myc antisense nucleotides. J. Clin. Invest. (1994) 93:820–828.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, GIBBONS GH, KANEDA Y et al.: Pharma-cokinetics of antisense oligonucleotides (cyclin B1 and cdc-2 kinase) in the vessel wall: enhanced thera-peutic utility for restenosis by HVJ-liposome method. Gene (1994) 149:13–19.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, GIBBONS GH, ELLISON KE et al: Single in-traluminal delivery of antisense cdc-2 kinase and PCNA oligonucleotides result in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA (1993) 90:8474–8479.
   PubMed Web of Science ®Google Scholar
• AUTIERI MV, YUE TL, FERSTEIN GZ et al.: Antisense oli-gonucleotides to the p65 subunit of NF-KB inhibit hu-man vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem. Biophys. Res. Commun. (1995) 213:827–836.
   PubMed Web of Science ®Google Scholar
• SIROIS MG, SIMONS M, EDELMAN ER: Antisense nucleo-tide inhibition of PDGF beta receptor subunit expres-sion directs suppression of intimal thickening. Circulation (1997) 95:669–676.
   PubMed Web of Science ®Google Scholar
• BENNETT M, SCHWARTZ S: Antisense therapy for angio-plasty restenosis. Some critical considerations. Circu-lation (1995) 92:1981–1993.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, GIBBONS GH, ELLISON KE et al.: Intimal hyperplasia after vascular injury is inhibited by an-tisense cdk-2 kinase oligonucleotides. j Clin. Invest. (1994) 93:1458–1464.
   PubMed Web of Science ®Google Scholar
• MORISHITA R, GIBBONS GH, HORIUCHI M et al.: A novelmolecular strategy using cis element 'decoy' of E2G binding site inhibits smooth muscle proliferation in vivo. Proc. Nati Acad. Sci. USA (1995) 92:5855–5859.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, CALIFF RM, WEISMAN HF: Randomised trialof coronary intervention with antibody against plate-let Ilb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet (1994) 343:881–886.
   PubMed Web of Science ®Google Scholar
• HAASE KK, MAHRHOLDT H, SCHRODER S et al: Fre-quency and efficacy of glycoprotein Ilb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty. Am. Heart 1 (1999) 137(2)234–240.
   Google Scholar
• PANDA D, KUNDU GC, LEE BI et al.: Potential roles of os-teopontin and alphaVbeta3 integrin in the develop-ment of coronary artery restenosis after angioplasty. Proc. Nati Acad. Sci. USA (1997) 94(17):9308–9313.
   PubMed Web of Science ®Google Scholar
• NAKADA MT, JORDAN RE, KNIGHT DM: Abciximab (Reo-Pro, chimeric 7E3 Fab): cross specificity with alpha-V-beta-3 integrin receptors: a potential mechanism for the prevention of restenosis. J. Am. Coll. Cardiol (1997) 29:243A.
   Google Scholar
• SRIVATSA SS, FITZPATRICK LA, TSAO PW et al.: SelectivealphaVbeta3 integrin blockade potently limits neointi-mal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the func-tional importance of integrin alphaVbeta3 and osteo-pontin expression during neointima formation. Cardio. Res. (1997) 36:408–428.
   PubMed Web of Science ®Google Scholar
• FERNS GAA, RAINES EW, SPRUGEL KH et al.: Anti-PDGFantibody significantly inhibits neointimal smooth muscle accumulation after angioplasty. Science (1991) 253:1129–1132.
   PubMedGoogle Scholar
• LINDNER V, REIDY MA: Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA (1991) 83:3739–3743.
   Google Scholar
• NIKOL S, ISNER JM, PICKERING JG et al.: Expression of transforming growth factor-beta I is increased in hu-man vascular restenosis lesions. J. Clin. Invest. (1992) 90:1582–1592.
   PubMedGoogle Scholar
• NIKOL S, WEIR L, SULLIVAN A et al.: Persistently in-creased expression of the transforming growth fac - tor-611 gene in human vascular restenosis: analysis of 62 patients with one or more episodes of restenosis. Cardiovasc. Pathol. (1994) 3:57–64.
   PubMedGoogle Scholar
• BATTEGAY EJ, RAINES EW, SEIFERT RA et al.: TGF-beta in-duces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell (1990) 63:515–524.
   PubMed Web of Science ®Google Scholar
• LIAW L, LOMBARDI DM, ALMEDIA MM et al.: Neutralizing antibodies directed against osteopontin inhibits rat ca-rotid neointimal thickening after endothelial denuda-tion. Arterioscler. Thromb. Vasc. Biol. (1997) 17:188–193.
   PubMed Web of Science ®Google Scholar
• LUDIA C, DOMENICO P, MONIA C et al.: Antiphos-pholipid antibodies: a new risk factor for restenosis after percutaneous transluminal coronary angio-plasty? A utoimmunity (1998) 27:141–148.
   Google Scholar
• PICKERING JG, BACHA PA, WEIR L et al.: Prevention ofsmooth muscle outgrowth from human atheroscle-rotic plaque by a recombinant cytoxin specific for the epidermal growth factor receptor. J. Clin. Invest. (1993) 91:724–729.
   PubMed Web of Science ®Google Scholar
• NIKOL S, MAIER A, KRAUSZ E et al.: Current biotechno-logical approaches to the prevention of restenosis. Biodrugs (1998) 9:375–388.
   PubMedGoogle Scholar
• ••Reviews some recombinant approaches for the treatment ofrestenosis.
   Google Scholar
• PENNISI E: Training viruses to attack cancers. Science (1998) 282:1244–1246.
   PubMedGoogle Scholar
• TYLER KL, FIELDS BN: In: Virology. Fields BN, Knipe DM, Howley PM (Eds.), Lippencott-Raven, Philadelphia, USA (1996):1597–1623.
   Google Scholar
• COFFEY MC, STRONG JE, FORSYTH PA et al.: Reovirus therapy of tumors with activated Ras pathway. Science (1998) 282:1332–1334.
   PubMed Web of Science ®Google Scholar
• LOWE PN, SKINNER RH: Regulation of Ras signal trans-duction in normal and transformed cells. Cell Signal. (1994) 6:109–123.
   PubMed Web of Science ®Google Scholar
• LEVITZKI A: Signal transduction therapy. A novel ap-proach to disease management. Eur. J. Biochem. (1994) 226:1–13.
   PubMedGoogle Scholar
• MIANO J, TOTA R, VLASIC N et al: Early proto-oncogeneexpression in rat aortic smooth muscle cells following endothelial removal. Am. J. Pathol (1990) 137:761–765.
   PubMed Web of Science ®Google Scholar